BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 24580738)

  • 1. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
    Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
    Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
    Eckmann C; Nathwani D; Lawson W; Corman S; Solem C; Stephens J; Macahilig C; Li J; Charbonneau C; Baillon-Plot N; Haider S
    Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S33-9. PubMed ID: 26198370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the place of linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia and complicated skin and soft tissue infections in Europe?
    Dumitrescu O; Lina G
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():1-2. PubMed ID: 24580737
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
    Bounthavong M; Hsu DI; Okamoto MP
    Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of linezolid in the treatment of complicated skin and soft tissue infections.
    Peppard WJ; Weigelt JA
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
    Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
    Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Napolitano LM
    Surg Infect (Larchmt); 2008; 9 Suppl 1():s17-27. PubMed ID: 18844471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.